CA2901016A1 - Systems and methods for collecting and transmitting assay results - Google Patents
Systems and methods for collecting and transmitting assay results Download PDFInfo
- Publication number
- CA2901016A1 CA2901016A1 CA2901016A CA2901016A CA2901016A1 CA 2901016 A1 CA2901016 A1 CA 2901016A1 CA 2901016 A CA2901016 A CA 2901016A CA 2901016 A CA2901016 A CA 2901016A CA 2901016 A1 CA2901016 A1 CA 2901016A1
- Authority
- CA
- Canada
- Prior art keywords
- sample
- biological sample
- data
- clia
- laboratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 392
- 238000003556 assay Methods 0.000 title claims description 96
- 239000000523 sample Substances 0.000 claims abstract description 1078
- 239000012472 biological sample Substances 0.000 claims abstract description 444
- 238000012545 processing Methods 0.000 claims abstract description 264
- 230000036541 health Effects 0.000 claims abstract description 260
- 238000006243 chemical reaction Methods 0.000 claims abstract description 154
- 238000002360 preparation method Methods 0.000 claims abstract description 109
- 238000004458 analytical method Methods 0.000 claims description 253
- 210000004027 cell Anatomy 0.000 claims description 231
- 238000011158 quantitative evaluation Methods 0.000 claims description 186
- 239000003153 chemical reaction reagent Substances 0.000 claims description 120
- 238000004891 communication Methods 0.000 claims description 103
- 210000004369 blood Anatomy 0.000 claims description 72
- 239000008280 blood Substances 0.000 claims description 72
- 230000008569 process Effects 0.000 claims description 71
- 239000012530 fluid Substances 0.000 claims description 67
- 230000005540 biological transmission Effects 0.000 claims description 54
- 230000001105 regulatory effect Effects 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 39
- 238000011156 evaluation Methods 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 33
- 230000003287 optical effect Effects 0.000 claims description 32
- 230000006872 improvement Effects 0.000 claims description 25
- 238000012216 screening Methods 0.000 claims description 22
- 238000003745 diagnosis Methods 0.000 claims description 21
- 238000003018 immunoassay Methods 0.000 claims description 20
- 238000007826 nucleic acid assay Methods 0.000 claims description 19
- 238000007824 enzymatic assay Methods 0.000 claims description 18
- 210000002700 urine Anatomy 0.000 claims description 17
- 238000007830 receptor-based assay Methods 0.000 claims description 15
- 210000003097 mucus Anatomy 0.000 claims description 14
- 230000028327 secretion Effects 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 210000003296 saliva Anatomy 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 206010050337 Cerumen impaction Diseases 0.000 claims description 10
- 210000002939 cerumen Anatomy 0.000 claims description 10
- 230000002496 gastric effect Effects 0.000 claims description 9
- 230000000762 glandular Effects 0.000 claims description 9
- 210000004243 sweat Anatomy 0.000 claims description 9
- 210000001138 tear Anatomy 0.000 claims description 9
- 238000001574 biopsy Methods 0.000 claims description 8
- 210000004905 finger nail Anatomy 0.000 claims description 7
- 210000004209 hair Anatomy 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 206010036790 Productive cough Diseases 0.000 claims description 5
- 210000004381 amniotic fluid Anatomy 0.000 claims description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 5
- 230000029142 excretion Effects 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 235000020256 human milk Nutrition 0.000 claims description 5
- 210000004251 human milk Anatomy 0.000 claims description 5
- 210000001006 meconium Anatomy 0.000 claims description 5
- 230000003169 placental effect Effects 0.000 claims description 5
- 210000003802 sputum Anatomy 0.000 claims description 5
- 208000024794 sputum Diseases 0.000 claims description 5
- 241000736262 Microbiota Species 0.000 claims description 4
- 230000001926 lymphatic effect Effects 0.000 claims description 4
- 210000004915 pus Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 238000012360 testing method Methods 0.000 description 230
- 238000012795 verification Methods 0.000 description 57
- 238000005259 measurement Methods 0.000 description 54
- 230000008901 benefit Effects 0.000 description 51
- 238000003384 imaging method Methods 0.000 description 50
- 239000000243 solution Substances 0.000 description 44
- 239000012491 analyte Substances 0.000 description 42
- 230000009471 action Effects 0.000 description 37
- 238000012552 review Methods 0.000 description 36
- 150000007523 nucleic acids Chemical class 0.000 description 35
- 102000004190 Enzymes Human genes 0.000 description 34
- 108090000790 Enzymes Proteins 0.000 description 34
- 229940088598 enzyme Drugs 0.000 description 34
- 108020004707 nucleic acids Proteins 0.000 description 32
- 102000039446 nucleic acids Human genes 0.000 description 32
- 238000013500 data storage Methods 0.000 description 30
- 239000000975 dye Substances 0.000 description 29
- 238000007781 pre-processing Methods 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- 238000001514 detection method Methods 0.000 description 28
- 239000000758 substrate Substances 0.000 description 28
- 230000008859 change Effects 0.000 description 26
- 210000001124 body fluid Anatomy 0.000 description 25
- 238000004163 cytometry Methods 0.000 description 24
- 239000002245 particle Substances 0.000 description 24
- 238000000386 microscopy Methods 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 230000002068 genetic effect Effects 0.000 description 19
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 102000001554 Hemoglobins Human genes 0.000 description 17
- 108010054147 Hemoglobins Proteins 0.000 description 17
- 230000003321 amplification Effects 0.000 description 17
- 230000007613 environmental effect Effects 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 230000001413 cellular effect Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000010234 longitudinal analysis Methods 0.000 description 14
- -1 simians Species 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 238000009739 binding Methods 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 238000012544 monitoring process Methods 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 238000007405 data analysis Methods 0.000 description 12
- 238000004566 IR spectroscopy Methods 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 238000005534 hematocrit Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000003908 quality control method Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 10
- 230000006806 disease prevention Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 238000005286 illumination Methods 0.000 description 10
- 229910052700 potassium Inorganic materials 0.000 description 10
- 239000011591 potassium Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000011514 reflex Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 239000005995 Aluminium silicate Substances 0.000 description 8
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 8
- 235000012211 aluminium silicate Nutrition 0.000 description 8
- 150000001450 anions Chemical class 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000005345 coagulation Methods 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 238000007398 colorimetric assay Methods 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 238000004848 nephelometry Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000007811 spectroscopic assay Methods 0.000 description 7
- 238000004879 turbidimetry Methods 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 238000000149 argon plasma sintering Methods 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 102000013415 peroxidase activity proteins Human genes 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 238000000711 polarimetry Methods 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 238000007818 agglutination assay Methods 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 238000007816 calorimetric assay Methods 0.000 description 5
- 238000007819 clotting time assay Methods 0.000 description 5
- 238000007820 coagulation assay Methods 0.000 description 5
- 238000007821 culture assay Methods 0.000 description 5
- 238000007822 cytometric assay Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000007812 electrochemical assay Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000834 fixative Substances 0.000 description 5
- 238000007825 histological assay Methods 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 238000007814 microscopic assay Methods 0.000 description 5
- 238000007827 osmolarity assay Methods 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000007828 protein synthesis assay Methods 0.000 description 5
- 238000007829 radioisotope assay Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000002798 spectrophotometry method Methods 0.000 description 5
- 238000007815 topographic assay Methods 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 238000007831 viscometric assay Methods 0.000 description 5
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 4
- 108091092878 Microsatellite Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 238000013475 authorization Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 238000007813 chromatographic assay Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 230000005670 electromagnetic radiation Effects 0.000 description 4
- 238000007823 electrophoretic assay Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000010287 polarization Effects 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000005236 sound signal Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108700020962 Peroxidase Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- YZVWKHVRBDQPMQ-UHFFFAOYSA-N aminoantipyrene Natural products C1=C2C(N)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 YZVWKHVRBDQPMQ-UHFFFAOYSA-N 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000011901 isothermal amplification Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000006148 magnetic separator Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BYMZHAPPSICVQH-UHFFFAOYSA-N 2-amino-4-hydroxybenzenesulfonic acid Chemical compound NC1=CC(O)=CC=C1S(O)(=O)=O BYMZHAPPSICVQH-UHFFFAOYSA-N 0.000 description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 2
- NEGFNJRAUMCZMY-UHFFFAOYSA-N 3-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=CC(C(O)=O)=C1 NEGFNJRAUMCZMY-UHFFFAOYSA-N 0.000 description 2
- MGUKYHHAGPFJMC-UHFFFAOYSA-N 4-[3-(4-hydroxy-2,5-dimethylphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-2,5-dimethylphenol Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC(O)=C(C)C=2)C)=C1C MGUKYHHAGPFJMC-UHFFFAOYSA-N 0.000 description 2
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000031872 Body Remains Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 125000002680 canonical nucleotide group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000002359 drug metabolite Substances 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 238000001413 far-infrared spectroscopy Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000013101 initial test Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001000 lipidemic effect Effects 0.000 description 2
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 238000013102 re-test Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PRZSXZWFJHEZBJ-UHFFFAOYSA-N thymol blue Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC(O)=C(C(C)C)C=2)C)=C1C PRZSXZWFJHEZBJ-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 239000002888 zwitterionic surfactant Substances 0.000 description 2
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- OLQIKGSZDTXODA-UHFFFAOYSA-N 4-[3-(4-hydroxy-2-methylphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-3-methylphenol Chemical compound CC1=CC(O)=CC=C1C1(C=2C(=CC(O)=CC=2)C)C2=CC=CC=C2S(=O)(=O)O1 OLQIKGSZDTXODA-UHFFFAOYSA-N 0.000 description 1
- FEPBITJSIHRMRT-UHFFFAOYSA-N 4-hydroxybenzenesulfonic acid Chemical compound OC1=CC=C(S(O)(=O)=O)C=C1 FEPBITJSIHRMRT-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- OHKQCSQQXNZTHC-UHFFFAOYSA-N C1=CC=CC2=NC3=CC=CC=C3C(=C12)C(=O)O.C1=CC=CC2=NC3=CC=CC=C3C=C12 Chemical class C1=CC=CC2=NC3=CC=CC=C3C(=C12)C(=O)O.C1=CC=CC2=NC3=CC=CC=C3C=C12 OHKQCSQQXNZTHC-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020001738 DNA Glycosylase Proteins 0.000 description 1
- 102000028381 DNA glycosylase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022005 Influenza viral infections Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 108010007843 NADH oxidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 1
- CBMCZKMIOZYAHS-NSCUHMNNSA-N [(e)-prop-1-enyl]boronic acid Chemical compound C\C=C\B(O)O CBMCZKMIOZYAHS-NSCUHMNNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- YVJPMMYYRNHJAU-UHFFFAOYSA-N chembl1206021 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)[N+]([O-])=O)=C1 YVJPMMYYRNHJAU-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000001344 confocal Raman microscopy Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- OBRMNDMBJQTZHV-UHFFFAOYSA-N cresol red Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 OBRMNDMBJQTZHV-UHFFFAOYSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- SUXCALIDMIIJCK-UHFFFAOYSA-L disodium;4-amino-3-[[4-[4-[(1-amino-4-sulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]naphthalene-1-sulfonate Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(N=NC3=CC=C(C=C3C)C=3C=C(C(=CC=3)N=NC=3C(=C4C=CC=CC4=C(C=3)S([O-])(=O)=O)N)C)=CC(S([O-])(=O)=O)=C21 SUXCALIDMIIJCK-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000005401 electroluminescence Methods 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000004374 forensic analysis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 1
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 229960003988 indigo carmine Drugs 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 238000001307 laser spectroscopy Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940051142 metanil yellow Drugs 0.000 description 1
- NYGZLYXAPMMJTE-UHFFFAOYSA-M metanil yellow Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC(N=NC=2C=CC(NC=3C=CC=CC=3)=CC=2)=C1 NYGZLYXAPMMJTE-UHFFFAOYSA-M 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- VXLFYNFOITWQPM-UHFFFAOYSA-N n-phenyl-4-phenyldiazenylaniline Chemical compound C=1C=C(N=NC=2C=CC=CC=2)C=CC=1NC1=CC=CC=C1 VXLFYNFOITWQPM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000004060 quinone imines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical class C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000000682 scanning probe acoustic microscopy Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- MLVYOYVMOZFHIU-UHFFFAOYSA-M sodium;4-[(4-anilinophenyl)diazenyl]benzenesulfonate Chemical compound [Na+].C1=CC(S(=O)(=O)[O-])=CC=C1N=NC(C=C1)=CC=C1NC1=CC=CC=C1 MLVYOYVMOZFHIU-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000003963 x-ray microscopy Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00584—Control arrangements for automatic analysers
- G01N35/00722—Communications; Identification
- G01N35/00871—Communications between instruments or with remote terminals
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00584—Control arrangements for automatic analysers
- G01N35/00722—Communications; Identification
- G01N35/00871—Communications between instruments or with remote terminals
- G01N2035/00881—Communications between instruments or with remote terminals network configurations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361766095P | 2013-02-18 | 2013-02-18 | |
US13/769,798 | 2013-02-18 | ||
US61/766,095 | 2013-02-18 | ||
US13/769,798 US9619627B2 (en) | 2011-09-25 | 2013-02-18 | Systems and methods for collecting and transmitting assay results |
PCT/US2014/016593 WO2014127285A1 (en) | 2013-02-18 | 2014-02-14 | Systems and methods for collecting and transmitting assay results |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2901016A1 true CA2901016A1 (en) | 2014-08-21 |
Family
ID=51354590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2901016A Abandoned CA2901016A1 (en) | 2013-02-18 | 2014-02-14 | Systems and methods for collecting and transmitting assay results |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2956755A4 (zh) |
JP (1) | JP2016508610A (zh) |
KR (1) | KR20150119407A (zh) |
CN (2) | CN105164508B (zh) |
AU (2) | AU2014216060A1 (zh) |
BR (1) | BR112015019315A2 (zh) |
CA (1) | CA2901016A1 (zh) |
HK (1) | HK1218572A1 (zh) |
IL (1) | IL240568A0 (zh) |
MX (2) | MX354033B (zh) |
SG (1) | SG11201506421PA (zh) |
WO (1) | WO2014127285A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3921840A4 (en) * | 2019-02-06 | 2022-03-23 | Siemens Healthcare Diagnostics, Inc. | PATIENT ID AND SAMPLE ID WORKFLOW METHOD AND DEVICE TO ENABLE DIAGNOSTIC TESTING |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010101671A1 (en) | 2009-01-16 | 2010-09-10 | New York University | Automated real-time particle characterization and three-dimensional velocimetry with holographic video microscopy |
CN105683751B (zh) | 2013-09-06 | 2020-01-17 | 赛拉诺斯知识产权有限责任公司 | 用于接收拭子的装置、系统、方法和套件 |
JP2016042836A (ja) * | 2014-08-25 | 2016-04-04 | 富士フイルム株式会社 | 検査通知出力装置、検査通知出力方法、検査通知出力プログラム、及び遺伝子染色体検査システム |
WO2016064917A1 (en) * | 2014-10-21 | 2016-04-28 | The Trustees Of Princeton University | Systems and methods for personalized sample analysis |
ES2913524T3 (es) | 2014-11-12 | 2022-06-02 | Univ New York | Huellas coloidales para materiales blandos usando caracterización holográfica total |
EP3414517B1 (en) * | 2016-02-08 | 2021-10-06 | New York University | Holographic characterization of protein aggregates |
JP7078539B2 (ja) * | 2016-02-25 | 2022-05-31 | エフ.ホフマン-ラ ロシュ アーゲー | ハンドヘルド分析装置の品質評価のための方法およびシステム |
CN105866118B (zh) * | 2016-06-04 | 2018-08-24 | 深圳灵喵机器人技术有限公司 | 一种动物排泄物成分检测系统及方法 |
US10976329B2 (en) * | 2016-10-07 | 2021-04-13 | Boehringer Ingelheim Vetmedica Gmbh | Method and system for testing a sample |
CN106682685B (zh) * | 2016-12-06 | 2020-05-01 | 重庆大学 | 基于微波加热温度场分布特征深度学习的局部温度变化异常检测方法 |
JP6875137B2 (ja) | 2017-01-31 | 2021-05-19 | シスメックス株式会社 | 精度管理方法、精度管理システム、管理装置、分析装置および精度管理異常判定方法 |
JP7009071B2 (ja) * | 2017-03-30 | 2022-01-25 | シスメックス株式会社 | フローサイトメータ及び粒子の検出方法 |
CN107034968A (zh) * | 2017-05-03 | 2017-08-11 | 深圳市高润电子有限公司 | 全自动无线互联网云智能坐便器及基因检测方法 |
CN107192825A (zh) * | 2017-07-31 | 2017-09-22 | 重庆微奥云生物技术有限公司 | 一种病毒抗体检测系统及方法 |
CN108198590A (zh) * | 2017-12-27 | 2018-06-22 | 四川南格尔生物科技有限公司 | 一种智能化血浆采集系统 |
CL2018000802A1 (es) * | 2018-03-28 | 2018-09-14 | Protome Spa | Dispositivo móvil que permite la detección de microorganismos determinados en distintos tipos de muestras |
KR102074150B1 (ko) * | 2018-04-11 | 2020-02-06 | 바디텍메드(주) | 복수의 진단 카트리지 세트의 반응특성 정보 변경 시스템 및 방법 |
JP2020041928A (ja) * | 2018-09-11 | 2020-03-19 | 株式会社東芝 | セルフチェックシステム |
JP7201297B2 (ja) * | 2018-09-26 | 2023-01-10 | シスメックス株式会社 | フローサイトメーター、データ送信方法及び情報処理システム |
CN114127535A (zh) * | 2019-06-19 | 2022-03-01 | 深圳迈瑞动物医疗科技有限公司 | 一种细胞分析仪、基于阻抗法对白细胞进行分类的方法及计算机可读存储介质 |
US11543338B2 (en) | 2019-10-25 | 2023-01-03 | New York University | Holographic characterization of irregular particles |
US11948302B2 (en) | 2020-03-09 | 2024-04-02 | New York University | Automated holographic video microscopy assay |
KR102460010B1 (ko) * | 2020-07-15 | 2022-10-27 | 소지영 | 난임 관련 서비스 제공 방법 및 그 방법을 수행하는 서버 |
CN111832961B (zh) * | 2020-07-23 | 2023-04-28 | 河南省计量科学研究院 | 电网的高压冲击测量装置及方法 |
CN112229668A (zh) * | 2020-09-10 | 2021-01-15 | 宠米(北京)科技有限公司 | 便携式宠物粪便监测设备 |
WO2022074577A1 (en) * | 2020-10-07 | 2022-04-14 | Gottardo Advisory Limited | Apparatus and method for acquiring and analyzing biological samples |
KR102331507B1 (ko) * | 2020-10-23 | 2021-12-01 | 이종수 | Qr/2차원바코드 스왑 키트를 이용한 식품 위생 검사 시스템 및 방법 |
CN113962252B (zh) * | 2021-09-16 | 2023-07-18 | 深圳市国赛生物技术有限公司 | 凝血时间计算方法、装置、系统与可读存储介质 |
CN114200151A (zh) * | 2022-02-17 | 2022-03-18 | 宁波海壹生物科技有限公司 | 一种全自动化学发光免疫分析仪管理系统 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5186162A (en) | 1988-09-14 | 1993-02-16 | Interpore Orthopaedics, Inc. | Ultrasonic transducer device for treatment of living tissue and/or cells |
AU5645690A (en) | 1989-05-05 | 1990-11-29 | Lifecodes Corporation | Method for genetic analysis of a nucleic acid sample |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
DK0408295T3 (da) | 1989-07-11 | 1996-09-16 | Gen Probe Inc | Fremgangsmåder til opformering af nukleinsyresekvenser |
US5527670A (en) | 1990-09-12 | 1996-06-18 | Scientific Generics Limited | Electrochemical denaturation of double-stranded nucleic acid |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
KR960703174A (ko) | 1993-06-09 | 1996-06-19 | 미안 알렉 | 자기장 순환식 반응방법(magnetic cycle reaction) |
EP0750680B1 (en) | 1994-03-15 | 1999-01-13 | Scientific Generics Ltd | Electrochemical denaturation of double-stranded nucleic acid |
US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US5939291A (en) | 1996-06-14 | 1999-08-17 | Sarnoff Corporation | Microfluidic method for nucleic acid amplification |
GB9706654D0 (en) | 1997-04-02 | 1997-05-21 | Scient Generics Ltd | Disassociation of interacting molecules |
WO1998045474A1 (en) | 1997-04-04 | 1998-10-15 | Innogenetics N.V. | Isothermal polymerase chain reaction by cycling the concentration of divalent metal ions |
DE69937223T3 (de) | 1998-11-09 | 2011-05-05 | Eiken Kagaku K.K. | Verfahren zur synthese von nukleinsäuren |
GB9903906D0 (en) | 1999-02-19 | 1999-04-14 | Microbiological Res Authority | Method and apparatus for nucleic acid strand separation |
EP1218542B1 (en) | 1999-09-13 | 2004-03-24 | Nugen Technologies, Inc. | Methods and compositions for linear isothermal amplification of polynucleotide sequences |
US6929636B1 (en) | 2000-11-08 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Internal drug dispenser capsule medical device |
US7567913B2 (en) * | 2001-02-16 | 2009-07-28 | Quest Diagnostics Inc. | Method and system for ordering a laboratory test for a patient and obtaining results thereof |
BR0205268A (pt) | 2001-03-09 | 2004-11-30 | Nugen Technologies Inc | Processos e composições para a mplificação de sequências de rna |
FI112093B (fi) | 2002-01-30 | 2003-10-31 | Boreal Plant Breeding Ltd | Menetelmä ja testipakkaus geneettisen identiteetin osoittamiseksi |
US20040038385A1 (en) | 2002-08-26 | 2004-02-26 | Langlois Richard G. | System for autonomous monitoring of bioagents |
JP4632788B2 (ja) | 2002-09-20 | 2011-02-16 | ニュー・イングランド・バイオラブズ・インコーポレイティッド | 核酸のヘリカーゼ依存性増幅 |
US20040260782A1 (en) * | 2003-01-31 | 2004-12-23 | Affleck Rhett L. | Data communication in a laboratory environment |
DE10315242B4 (de) * | 2003-04-03 | 2006-02-23 | Siemens Ag | Verfahren und Vorrichtung zur realitätsnahen dreidimensionalen Bildgebung |
KR20140134338A (ko) | 2003-09-11 | 2014-11-21 | 테라노스, 인코포레이티드 | 피분석물의 모니터링 및 약물 전달을 위한 의료 기기 |
US20080262321A1 (en) * | 2004-08-06 | 2008-10-23 | Ramot At Tel Aviv University Ltd. | Early Detection of Harmful Agents: Method, System and Kit |
US20060074294A1 (en) * | 2004-10-06 | 2006-04-06 | E-Z-Em, Inc. | Medical imaging system, dispensing system, method, and computer program product for assessing patient renal function prior to dispensing a contrast media as part of a medical imaging procedure |
US20060194325A1 (en) * | 2005-02-14 | 2006-08-31 | Gable Jennifer H | Fluid handling cassette with a fluid control interface |
EP1866434B1 (en) | 2005-02-19 | 2013-06-05 | Avacta Group plc | Isothermal nucleic acid amplification |
SI1889198T1 (sl) | 2005-04-28 | 2015-02-27 | Proteus Digital Health, Inc. | Farma-informacijski sistem |
US7635594B2 (en) * | 2005-05-09 | 2009-12-22 | Theranos, Inc. | Point-of-care fluidic systems and uses thereof |
AU2006261953B2 (en) * | 2005-06-24 | 2012-02-23 | Board Of Regents, The University Of Texas System | Systems and methods including self-contained cartridges with detection systems and fluid delivery systems |
EA007146B1 (ru) * | 2005-07-13 | 2006-08-25 | Давид Георгиевич Хидашели | Способ и система анализа характеристик жидких сред биологических организмов |
JP5175213B2 (ja) | 2005-12-22 | 2013-04-03 | ハネウェル・インターナショナル・インコーポレーテッド | 携帯用サンプル分析システム |
US7657070B2 (en) * | 2006-01-20 | 2010-02-02 | Sakura Finetek U.S.A., Inc. | Automated system of processing biological specimens and method |
CN101583722A (zh) * | 2006-07-14 | 2009-11-18 | 阿维瓦生物科学股份有限公司 | 从生物学样品检测稀有细胞的方法和组合物 |
US8771930B2 (en) * | 2007-05-18 | 2014-07-08 | Lifeline Scientific, Inc. | Ex vivo methods for testing toxicity of substances using donated human organs or tissues |
CA2934220C (en) * | 2007-10-02 | 2019-11-05 | Theranos, Inc. | Modular point-of-care devices and uses thereof |
SG177937A1 (en) | 2008-03-26 | 2012-02-28 | Theranos Inc | Methods and systems for assessing clinical outcomes |
CN102753977B (zh) * | 2009-07-27 | 2016-05-25 | 梅索磅秤技术有限公司 | 化验装置、耗材和方法 |
AR077286A4 (es) * | 2009-09-16 | 2011-08-17 | Unilever Nv | Dispositivo de toma de muestras para recomendar un producto destinado al cuidado personal adecuado para un cliente |
US8380541B1 (en) * | 2011-09-25 | 2013-02-19 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
-
2014
- 2014-02-14 AU AU2014216060A patent/AU2014216060A1/en not_active Abandoned
- 2014-02-14 EP EP14751655.3A patent/EP2956755A4/en not_active Withdrawn
- 2014-02-14 WO PCT/US2014/016593 patent/WO2014127285A1/en active Application Filing
- 2014-02-14 BR BR112015019315A patent/BR112015019315A2/pt not_active IP Right Cessation
- 2014-02-14 CA CA2901016A patent/CA2901016A1/en not_active Abandoned
- 2014-02-14 JP JP2015558168A patent/JP2016508610A/ja active Pending
- 2014-02-14 MX MX2015010479A patent/MX354033B/es active IP Right Grant
- 2014-02-14 KR KR1020157025660A patent/KR20150119407A/ko not_active Application Discontinuation
- 2014-02-14 CN CN201480021565.6A patent/CN105164508B/zh active Active
- 2014-02-14 SG SG11201506421PA patent/SG11201506421PA/en unknown
- 2014-02-14 CN CN201910172255.9A patent/CN109813923A/zh active Pending
-
2015
- 2015-08-13 MX MX2022001727A patent/MX2022001727A/es unknown
- 2015-08-13 IL IL240568A patent/IL240568A0/en unknown
-
2016
- 2016-06-07 HK HK16106499.5A patent/HK1218572A1/zh unknown
-
2018
- 2018-02-13 AU AU2018201047A patent/AU2018201047A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3921840A4 (en) * | 2019-02-06 | 2022-03-23 | Siemens Healthcare Diagnostics, Inc. | PATIENT ID AND SAMPLE ID WORKFLOW METHOD AND DEVICE TO ENABLE DIAGNOSTIC TESTING |
USD984466S1 (en) | 2019-02-06 | 2023-04-25 | Siemens Healthcare Diagnostics Inc. | Portion of a display screen with a graphical user interface having a progress indicator |
USD984467S1 (en) | 2019-02-06 | 2023-04-25 | Siemens Healthcare Diagnostics Inc. | Portion of a display screen with a graphical user interface having a progress indicator |
USD993967S1 (en) | 2019-02-06 | 2023-08-01 | Siemens Healthcare Diagnostics Inc. | Portion of a display screen with a graphical user interface having a progress indicator |
USD993981S1 (en) | 2019-02-06 | 2023-08-01 | Siemens Healthcare Diagnostics Inc. | Portion of a display screen with a graphical user interface having a progress indicator |
Also Published As
Publication number | Publication date |
---|---|
AU2018201047A1 (en) | 2018-03-29 |
IL240568A0 (en) | 2015-09-24 |
AU2014216060A1 (en) | 2015-08-20 |
WO2014127285A1 (en) | 2014-08-21 |
CN105164508A (zh) | 2015-12-16 |
MX2022001727A (es) | 2022-07-21 |
EP2956755A1 (en) | 2015-12-23 |
SG11201506421PA (en) | 2015-09-29 |
HK1218572A1 (zh) | 2017-02-24 |
CN109813923A (zh) | 2019-05-28 |
KR20150119407A (ko) | 2015-10-23 |
MX354033B (es) | 2018-02-09 |
CN105164508B (zh) | 2019-04-02 |
MX2015010479A (es) | 2016-02-18 |
EP2956755A4 (en) | 2016-03-30 |
JP2016508610A (ja) | 2016-03-22 |
BR112015019315A2 (pt) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9619627B2 (en) | Systems and methods for collecting and transmitting assay results | |
AU2018201047A1 (en) | Systems and methods for collecting and transmitting assay results | |
US20140335505A1 (en) | Systems and methods for collecting and transmitting assay results | |
US11257215B2 (en) | Systems and methods for collecting and transmitting assay results | |
US20130080071A1 (en) | Systems and methods for sample processing and analysis | |
Plebani et al. | Laboratory network of excellence: enhancing patient safety and service effectiveness | |
US20170329935A1 (en) | Systems and Methods for Collecting and Transmitting Assay Results | |
US10101349B2 (en) | Analytical test management system and method | |
Wesarachkitti et al. | Performance evaluation and comparison of the fully automated urinalysis analyzers UX-2000 and Cobas 6500 | |
JP2021035372A (ja) | サンプル分析のための方法、機器、及びシステム | |
Zemlin | Errors in the extra-analytical phases of clinical chemistry laboratory testing | |
Hernandez et al. | Comparison of the performance of the IDEXX SediVue Dx® with manual microscopy for the detection of cells and 2 crystal types in canine and feline urine | |
WO2013043204A1 (en) | Systems and methods for collecting and transmitting assay results | |
US20070239485A1 (en) | System and method for providing telediagnostic services | |
Pesce et al. | Saliva and the clinical pathology laboratory | |
Powless et al. | Evaluation of acridine orange staining for a semi-automated urinalysis microscopic examination at the point-of-care | |
Agrawal | Laboratory Diagnostics–Tools for Clinical Decision‐Making and Clinical Trial Endpoints | |
Grindstaff | Setbacks in Clinical Laboratory Innovations | |
Soares de Oliveira et al. | Simulated fine-needle aspiration diagnosis of follicular thyroid nodules by hyperspectral Raman microscopy and chemometric analysis | |
CHHATRIWALA et al. | Turn Around Time for Clinical Biochemistry Laboratory: A Vital and Effective Parameter for Patient Care. | |
Malucelli et al. | Validation of a Novel IoT and AI based Point-of-Care Testing Laboratory: Analytical Accuracy and Clinical Agreement | |
Secchi | 53rd National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC–Laboratory Medicine). | |
Gasparin et al. | Hilab System Device in an Oncological Hospital: A New Clinical Approach for Point of Care CBC Test, Supported by the Internet of Things and Machine Learning. Diagnostics 2023, 13, 1695 | |
Ragosta et al. | Sperm Chromatin Dispersion Test Detects Sperm DNA Fragmentation Mainly Associated with Unviable Spermatozoa and Underestimates the Values with Respect to TUNEL Assay | |
WO2015191716A2 (en) | Methods, devices, and systems for sample analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20190131 |
|
FZDE | Discontinued |
Effective date: 20221004 |
|
FZDE | Discontinued |
Effective date: 20221004 |